Kanishka Pothula
Partner @ Nextech Invest
San Francisco, United States
Kanishka Pothula is a Series B investor at Nextech Invest in San Francisco focused on Biotechnology and Health Care. Kanishka Pothula is based out of San Francisco, California and is the Partner of Nextech. Kanishka previously worked at BVF Partners. Kanishka Pothula attended the Georgetown University.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 62%
Last updated:
For AI agents: llms.txt
Industries Kanishka Pothula invests in
Stages Kanishka Pothula invests in
Countries Kanishka Pothula invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (62%)
- Health Care 7 (54%)
- Therapeutics 5 (38%)
- Pharmaceutical 4 (31%)
- Medical 2 (15%)
Stage
- Series B 5 (38%)
- Series C 3 (23%)
- Post-IPO Equity 3 (23%)
Country
- United States 7 (54%)
- Germany 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology. | $150M / Series B / Oct 07, 2026 | ||
| Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | ||
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M / Series C / Oct 15, 2025 | ||
| ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $125M / Post-IPO Equity / May 28, 2025 | ||
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $139.3M / Series B / Mar 14, 2024 | ||
| Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.The company's platform detects and characterizes interactions that occur anywhere on a protein and combines computational methods with experimental approaches across the fields of structural biology,biophysics and chemistry, enabling pharmaceutical companies to solve and design therapies against complex diseases like cancer and others. | $30M / Post-IPO Equity / Jan 08, 2024 | ||
| Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused onthree core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy. | $80M / Post-IPO Equity / Aug 10, 2023 | ||
| ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments. | $85M / Post-IPO Equity / Jun 26, 2023 | ||
| Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential toreprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. | $78M / Series B / Oct 05, 2021 | ||
| Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.The company's platform detects and characterizes interactions that occur anywhere on a protein and combines computational methods with experimental approaches across the fields of structural biology,biophysics and chemistry, enabling pharmaceutical companies to solve and design therapies against complex diseases like cancer and others. | $400M / Series C / Dec 20, 2018 | ||
| See all 13 investments → | |||
Co-Investors
About Nextech Invest
Nextech Invest is a venture capital and private equity firm specializing in early, mid-stage, late-stage, and emerging growth investments. The firm also invests in incorporation, spin-outs, reverse-take-over, and PIPE transactions. It only considers investments where evidence in preclinical animal models that a drug is efficacious is available or a device prototype fulfills the requirements. The firm seeks to invest in the field of information technology, biotechnology, and healthcare with a focus on oncology companies developing cancer drugs and diagnostics. It prefers to invest in life science and enabling technologies with a focus on interdisciplinary technical and scientific projects, therapies, diagnostics, medical technologies, and services. The firm seeks to invest in companies based in Africa, the Middle East, Asia, North America, and Europe including Switzerland, Germany, and neighboring regions. It also considers co-investments in the rest of Europe. The firm seeks to invest between CHF 1 million ($0.93 million) and CHF 5 million ($4.7 million) per financing round. It seeks a Board position in the portfolio companies. The firm seeks to exit its investments within three years via trade sale.
Nextech Invest Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kanishka Pothula
Partner
|
|||
Megan Graziano
Director Of Operations
|
|||
Melissa McCracken
Partner
|
|||
Thilo Schroeder
Managing Partner
|
|||
Thomas Geninatti
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kanishka Pothula invest in?
Kanishka Pothula invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kanishka Pothula?
Public channels for Kanishka Pothula include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kanishka Pothula last invest?
The most recent investment recorded for Kanishka Pothula closed in Oct 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
